Elahere (mirvetuximab soravtansine-gynx) Patient Assistance Program
Don’t let the high cost of brand folate receptor alpha-targeted antibody-drug conjugate disrupt your platinum-resistant ovarian cancer treatment. We help eligible patients access Elahere (mirvetuximab soravtansine-gynx intravenous infusion) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
Key Takeaways:
- Elahere (mirvetuximab soravtansine-gynx) is FDA-approved for adults with folate receptor alpha (FRα)-positive platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who received 1–3 prior systemic treatment regimens. First-in-class FRα-targeted antibody-drug conjugate (ADC) — anti-FRα antibody linked to DM4 maytansinoid microtubule disruptor.
- Without assistance, Elahere costs commonly run approximately $15,000–$20,000 per infusion (every 3 weeks).
- Through AffordMyPrescriptions, qualifying patients can access Elahere for a flat $69.95 per month.
- Other platinum-resistant ovarian cancer options: pegylated liposomal doxorubicin (Doxil — generic), weekly paclitaxel (generic), topotecan (generic), gemcitabine (generic), etoposide (generic) — single-agent chemo with modest response rates. Bevacizumab (Avastin biosimilars now available — Mvasi, Zirabev) often added. PARP inhibitor maintenance for BRCA-mutated or HRD-positive disease (Lynparza, Zejula, Rubraca). Antibody-drug conjugates and targeted therapies expanding in this space. FRα-positive testing (VENTANA FOLR1 IHC RxDx Assay) required for Elahere eligibility.
What is Elahere Prescription Assistance Program?
The Elahere Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Elahere (used for FRα-positive platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but the enrollment process involves detailed applications, gynecologic oncology coordination, FRα testing documentation, supporting documentation, and ongoing renewal — which can be overwhelming when you are managing platinum-resistant ovarian cancer.
At AffordMyPrescriptions, our Patient Advocates handle the entire Elahere PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your gynecologic oncologist for required medical documentation (typically including FRα testing results, prior therapy history, and clinical criteria), follow up with the manufacturer’s program until approval, manage your infusion cycles, and handle annual re-certification — so you never face a gap in your Elahere ADC therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Elahere enrollment — from the initial application through ongoing refills and annual re-enrollment — so you never face a gap in your platinum-resistant ovarian cancer treatment.
Pharmacy Price Comparison
- Without assistance, Elahere costs thousands of dollars per infusion at oncology centers and specialty pharmacies. Discount cards and pharmacy coupons offer minimal relief at this price point, but a Patient Assistance Program can make this targeted ovarian cancer therapy accessible if you qualify. The table below compares typical pricing across major settings to what you'd pay with our Elahere advocacy service:
| PHARMACY | PRICE (30-DAY) WITH BEST COUPONS | YOU SAVE W/ US |
|---|---|---|
| Generic single-agent chemo | ~$800/cycle | Generic chemo alt — lower response |
| Hospital oncology | ~$19,000/dose | Save substantially |
| Community oncology | ~$17,500/dose | Save substantially |
| Specialty pharmacy | ~$16,000/dose | Save substantially |
| 340B-eligible institution | ~$15,000/dose | Save substantially |
| Doxil + Avastin biosim (alt) | ~$5,000/cycle | Alt platinum-resistant regimen |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Elahere — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Elahere Prescription Program?
The Elahere Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — applications that are commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork. FRα testing is essential for Elahere candidacy.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for Elahere assistance.
We Advocate
Our specialists gather documentation, complete applications, and coordinate with your prescriber and the assistance program.
Receive Medication
Once approved, your Elahere is delivered through the assistance program while we manage refills and annual renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Elahere:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
Still $15,000–$20,000/dose per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
Medication supplied directly through the assistance program
We manage all paperwork, refills, and annual renewals
Medicare Part D patients accepted
If denied, we explore alternative savings paths on your behalf
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Elahere assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Elahere Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Elahere:
Elahere is a first-in-class FRα-targeted antibody-drug conjugate combining a mirvetuximab anti-FRα antibody with the DM4 maytansinoid microtubule inhibitor via a cleavable linker. FRα overexpression in approximately 35–40% of platinum-resistant ovarian cancers makes it a tumor-selective delivery target. MIRASOL trial demonstrated overall survival benefit vs investigator’s choice chemotherapy in FRα-high platinum-resistant ovarian cancer.
How It Works:
Platinum-resistant epithelial ovarian cancer (relapse within 6 months of platinum-based chemotherapy) has historically been a poor-prognosis disease with limited effective options and modest response rates to single-agent cytotoxic chemotherapy. Folate receptor alpha (FRα) is overexpressed in many ovarian cancers and provides a tumor-selective targeting opportunity. Mirvetuximab anti-FRα antibody binds tumor FRα on the cell surface — the ADC is internalized, the cleavable linker releases the DM4 maytansinoid payload — DM4 binds tubulin and disrupts microtubule polymerization, causing cell cycle arrest and apoptosis. The tumor-selective delivery improves the therapeutic index compared with systemic chemotherapy. The MIRASOL trial established overall survival benefit vs investigator’s choice chemotherapy in FRα-high platinum-resistant ovarian cancer.
Form and Use:
Elahere 6 mg/kg (adjusted ideal body weight) IV infusion every 3 weeks. Premedication with corticosteroid, antihistamine, antipyretic, and ophthalmic lubricants to mitigate infusion reactions and ocular toxicity. Continue until disease progression or unacceptable toxicity. Mandatory ophthalmologic baseline assessment and ongoing eye monitoring with optometry/ophthalmology referral for prophylactic eye care. Hold for grade 2+ ocular toxicity or other significant AEs.
Generic Availability:
No biosimilar/generic. Other platinum-resistant ovarian cancer therapies: pegylated liposomal doxorubicin (Doxil — generic), weekly paclitaxel (generic), topotecan (generic), gemcitabine (generic), etoposide (generic) — single-agent chemo with response rates typically 5–15%. Bevacizumab (Avastin biosimilars now available — Mvasi, Zirabev) often added to chemo. PARP inhibitor maintenance for BRCA-mutated or HRD-positive disease (Lynparza/olaparib, Zejula/niraparib, Rubraca/rucaparib). Other emerging ADCs in development. NCCN ovarian cancer guidelines guide platinum-resistant treatment selection. Genetic testing (BRCA1/2, HRD), FRα testing, and prior therapy history guide choice.
Warnings:
Boxed warning: ocular adverse reactions including visual impairment, keratopathy (corneal disease), dry eye, photophobia, eye pain, and uveitis — can be severe and impact vision; mandatory baseline eye exam, scheduled prophylactic eye drops (artificial tears, corticosteroid drops per labeling), and prompt ophthalmology referral for symptoms. Other: pneumonitis (sometimes severe — evaluate respiratory symptoms), peripheral neuropathy (sensory more than motor — monitor and dose-modify), embryo-fetal toxicity, neutropenia, thrombocytopenia, hepatotoxicity, infusion-related reactions. Periodic CBC, comprehensive metabolic panel, and ophthalmologic monitoring required.
FAQ (Frequently Asked Questions)
How much does Elahere cost without insurance?
$15,000–$20,000 per infusion. Annualized cost can exceed $250,000 without assistance. Specialty pharmacy and Patient Assistance Programs are essential for most patients to access this targeted ovarian cancer therapy.
Why is FRα testing required before starting Elahere?
Elahere is FDA-approved specifically for FRα-positive platinum-resistant ovarian cancer. The VENTANA FOLR1 IHC RxDx Assay measures FRα expression on tumor cells — only patients with FRα-high disease (≥75% of tumor cells with PS2+ staining) demonstrate the survival benefit observed in MIRASOL. Tumor tissue testing identifies appropriate candidates.
Is Elahere considered chemotherapy?
Elahere is an antibody-drug conjugate — it delivers a chemotherapy payload (DM4 maytansinoid) selectively to FRα-expressing tumor cells. Different from systemic chemotherapy in that the cytotoxic agent is targeted via the anti-FRα antibody, reducing exposure of healthy tissue and improving the therapeutic window.
Why is eye monitoring critical with Elahere?
Elahere carries a boxed warning for ocular toxicity — keratopathy, dry eye, photophobia, blurred vision, and uveitis can be severe and vision-threatening. Mandatory baseline eye examination, prophylactic lubricating and corticosteroid eye drops per labeling, and prompt ophthalmology referral for any new visual symptoms are essential. Most ocular toxicity is reversible with prompt management.
What is the difference between Elahere and other ovarian cancer therapies?
Elahere is the first FRα-targeted ADC for platinum-resistant ovarian cancer — provides targeted delivery of cytotoxic payload to FRα-expressing tumor cells. Standard chemotherapy options (PLD/Doxil, weekly paclitaxel, topotecan, gemcitabine, etoposide) are non-targeted systemic chemotherapy. Bevacizumab targets angiogenesis. PARP inhibitors (Lynparza, Zejula, Rubraca) target HR deficiency in BRCA-mutated or HRD-positive disease. Each addresses different biology.
Take Control of Your Medication Costs
Targeted therapy for FRα-positive platinum-resistant ovarian cancer should not be derailed by cost. FRα testing and proper patient selection are essential. Our Elahere advocacy team is ready to verify your eligibility, complete the manufacturer application on your behalf, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help you access Elahere through a Patient Assistance Program, you are not charged.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.